Mid Cap Stocks To Follow Now - October 16th

Key Points

• AltC Acquisition Corp. is a company seeking to merge or acquire other businesses, and it has recently changed its name from Churchill Capital Corp VIII.
• ProShares UltraPro Short QQQ (SQQQ) aims for daily investment results that correspond to three times the inverse of the NASDAQ-100 Index's performance.
• Praxis Precision Medicines (PRAX) focuses on developing therapies for central nervous system disorders and is currently conducting Phase III clinical trials for several treatments.

AltC Acquisition, ProShares UltraPro Short QQQ, and Praxis Precision Medicines are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with market capitalizations typically between roughly $2 billion and $10 billion. They generally offer a balance between the growth potential of small-cap firms and the relative stability of large-cap firms, making them attractive to investors seeking moderate growth with moderate risk. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Read Our Latest Research Report on ALCC

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

Read Our Latest Research Report on PRAX